Product Description
Key Product and Clinical Details
Physical Appearance & Formulation
- Form: Film-coated, oval-shaped yellow tablets.
- Debossing: Typically debossed with TUC on one side and 150 on the other.
- Dimensions: Approximately 17 mm in length and 7 mm in width.
- Classification: Tyrosine kinase inhibitor (TKI); it is not a traditional chemotherapy drug.
- Action: Selectively targets and blocks the HER2 receptor, halting the downstream signaling pathways that allow cancer cells to grow and multiply.
- Brain Penetration: It is uniquely capable of crossing the blood-brain barrier, making it highly effective against central nervous system metastases.
Approved Indications & Dosage
- Breast Cancer: Indicated in combination with trastuzumab and capecitabine for adults with locally advanced or metastatic HER2-positive breast cancer.
- Colorectal Cancer: Also used in combination with trastuzumab for RAS wild-type, HER2-positive metastatic colorectal cancer.
- Standard Dosage: The typical recommended dose is 300 mg (two 150 mg tablets) taken twice daily, roughly 12 hours apart.
Important Safety & Administration
- How to Take: Swallow the tablets whole with water. Do not chew, crush, split, or dissolve them.
- Food Intake: It can be taken with or without food.
- Common Side Effects: Diarrhea, nausea, vomiting, mouth sores, fatigue, rash, and hand-foot syndrome.
- Monitoring: Regular liver function tests and monitoring for severe diarrhea or dehydration are generally required during treatment.